

Supplementary Information

Cu^{II} immobilized on guanidinated epibromohydrin functionalized γ -Fe₂O₃@TiO₂ (γ -Fe₂O₃@TiO₂-EG-Cu^{II}): a novel magnetically recyclable heterogeneous nanocatalyst for the green one-pot synthesis of 1,4-disubstituted 1,2,3-triazoles through alkyne-azide cycloaddition in water

Roya Jahanshahi, Batool Akhlaghinia*

*Department of Chemistry, Faculty of Sciences, Ferdowsi University of Mashhad, Mashhad
9177948974, Iran.*

Experimental

General

The purity determinations of the products and the progress of the reactions were accomplished by TLC on silica gel polygram STL G/UV 254 plates. The melting points of the products were determined with an Electrothermal Type 9100 melting point apparatus. The FTIR spectra were recorded on pressed KBr pellets using an AVATAR 370 FT-IR spectrometer (Thermo Nicolet spectrometer, USA) at room temperature in the range between 4000 and 400 cm^{-1} with a resolution of 4 cm^{-1} , and each spectrum was the average of 32 scans. NMR spectra were recorded on a NMR Bruker Avance spectrometer at 400 and 300 MHz in CDCl_3 as solvent in the presence of tetramethylsilane as the internal standard and the coupling constants (J values) are given in Hz. Elemental analyses were performed using a Thermo Finnigan Flash EA 1112 Series instrument (furnace: 900 $^{\circ}\text{C}$, oven: 65 $^{\circ}\text{C}$, flow carrier: 140 mL min^{-1} , flow reference: 100 mL min^{-1}). Mass spectra were recorded with a CH7A Varianmat Bremem instrument at 70 eV electron impact ionization, in m/z (rel %). Thermogravimetric analyses (TGA and DTG) were carried out using a Shimadzu Thermogravimetric Analyzer (TG-50) in the temperature range of 25–900 $^{\circ}\text{C}$ at a heating rate of 10 $^{\circ}\text{C min}^{-1}$, under air atmosphere. HRTEM analysis was performed using HRTEM microscope (Philips CM30). Inductively coupled plasma (ICP) was carried out on a Varian, VISTA-PRO, CCD, Australia. Elemental compositions were determined with an SC7620 Energy-dispersive X-ray analysis (EDX) presenting a 133 eV resolution at 20 kV. Room temperature magnetization isotherms were obtained using a vibrating sample magnetometer (VSM, LakeShore 7400). X-ray powder diffraction (XRD) was performed on a X'Pert Pro MPD diffractometer with $\text{Cu K}\alpha$ ($\lambda = 0.154 \text{ nm}$) radiation. Most of the obtained triazoles (**4a-j**, **4m-p** and **4r-v**) were known and their physical (color, melting points) and spectral (mass spectrometry) data found to be identical with

those of authentic compounds. The selected compounds were further identified by FT-IR, ^1H NMR and ^{13}C NMR spectroscopy which compared with literature data. The novel synthesized compounds (**4k**, **4l** and **4q**) were also characterized by using elemental analysis technique. All yields refer to isolated products after purification by recrystallization.

1-Benzyl-4-phenyl-1*H*-1,2,3-triazole (4a) (0.22 g, 94%); white solid (crystals); mp 127-128 °C (from EtOH) (Lit.¹ 128–129 °C); FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3133, 3051, 2949, 1611, 1461 (CH_2), 1443, 1427, 1352, 1222 (N-N=N-), 1188 (C-N), 1072, 1049, 972, 914, 816 ($=\text{C-H}$ oop, triazole ring), 767, 720, 696, 581; ^1H NMR: δH (300 MHz; CDCl_3 ; Me_4Si) 7.83 (2 H, d, $J = 7.65$ Hz, Ar-H), 7.70 (1 H, s, C=CH), 7.44-7.38 (5 H, m, Ar-H), 7.36-7.29 (3 H, m, Ar-H), 5.58 (2 H, s, CH_2); ^{13}C NMR: δC (75 MHz; CDCl_3 ; Me_4Si) 148, 134, 130, 129, 128.83, 128.79, 128.18, 128.07, 125, 119, 54; MS, m/z 235 (M^+ , 13%), 234 (75, M-H), 206 (55, M-N_2), 129 (63, $\text{M-C}_7\text{H}_7\text{N}$), 116 (95, $\text{M-C}_8\text{H}_7\text{N}_2$), 104 (75, $\text{M-C}_8\text{H}_6\text{N}_2$), 91 (100, $\text{M-C}_8\text{H}_6\text{N}_3$), 77 (74, $\text{M-C}_9\text{H}_8\text{N}_3$), 29 (50, $\text{M-C}_{15}\text{H}_{13}\text{N}$).




Figure 1: FT-IR (KBr) of 1-Benzyl-4-phenyl-1*H*-1,2,3-triazole (**4a**).




Figure 2: ^1H NMR (300 MHz, CDCl_3) of 1-Benzyl-4-phenyl-1*H*-1,2,3-triazole (**4a**).




Figure 3: ^{13}C NMR (75MHz, CDCl_3) of 1-Benzyl-4-phenyl-1*H*-1,2,3-triazole (**4a**).




Figure 4: Mass spectrum of 1-Benzyl-4-phenyl-1*H*-1,2,3-triazole (**4a**).

1-Benzyl-4-(*p*-tolyl)-1*H*-1,2,3-triazole (4b**)** (0.23 g, 92%); white solid (crystals); mp 142-144 °C (from EtOH) (Lit.² 142–146 °C); FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3145, 3015, 2913, 1495, 1456 (CH_2), 1431, 1347, 1222 ($\text{N}=\text{N}=\text{N}-$), 1180 ($\text{C}-\text{N}$), 1065, 1046, 976, 827 ($=\text{C}-\text{H}$ oop, triazole ring), 793, 721, 583, 512; ^1H NMR: δH (300 MHz; CDCl_3 ; Me_4Si) 7.71 (2 H, d, $J = 8.1$ Hz, Ar-H), 7.65 (1 H, s, $\text{C}=\text{CH}$), 7.43-7.29 (5 H, m, Ar-H), 7.23 (2 H, d, $J = 7.8$ Hz, Ar-H), 5.59 (2 H, s, CH_2), 2.39 (3 H, s, CH_3); MS, m/z 249 (M^+ , 3%), 248 (32, $\text{M} - \text{H}$), 247 (86, $\text{M} - 2 \text{H}$), 220 (70, $\text{M} - \text{N}_2$), 130 (99, $\text{M} - \text{C}_8\text{H}_8\text{N}$), 115 (55, $\text{M} - \text{C}_7\text{H}_7\text{N}_3$), 103 (86, $\text{M} - \text{C}_9\text{H}_{10}\text{N}_2$), 91 (100, $\text{M} - \text{C}_9\text{H}_8\text{N}_3$), 77 (86, $\text{M} - \text{C}_{10}\text{H}_{10}\text{N}_3$), 28 (85, $\text{M} - \text{C}_{16}\text{H}_{15}\text{N}$).




Figure 5: FT-IR (KBr) of 1-Benzyl-4-(*p*-tolyl)-1*H*-1,2,3-triazole (4b).




Figure 6: ^1H NMR (300 MHz, CDCl_3) of 1-Benzyl-4-(*p*-tolyl)-1*H*-1,2,3-triazole (4b).




Figure 7: Mass spectrum of 1-Benzyl-4-(*p*-tolyl)-1*H*-1,2,3-triazole (**4b**).

1-Benzyl-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (4c**)** (0.24 g, 91%); white solid (crystals); mp 139–141 °C (from EtOH) (Lit.³ 140–142 °C); FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3137, 3035, 2966, 2952, 2855, 2835, 1617, 1580, 1556, 1500, 1455 (CH_2), 1352, 1266 ($\text{N}=\text{N}=\text{N}-$), 1250, 1221, 1172 ($\text{C}-\text{N}$), 1074, 1027, 980, 834 ($=\text{C}-\text{H}$ oop, triazole ring), 796, 720, 579; ^1H NMR: δH (300 MHz; CDCl_3 ; Me_4Si) 7.78–7.29 (8 H, m, Ar-H, $\text{C}=\text{CH}$), 6.96 (2 H, d, $J = 7.2$ Hz, Ar-H), 5.58 (2 H, s, CH_2), 3.85 (3 H, s, OCH_3); ^{13}C NMR: δC (75 MHz; CDCl_3 ; Me_4Si) 159, 148, 134, 129, 128.76, 128.08, 126, 123, 114, 55, 54; MS, m/z 265 (M^+ , 6%), 263 (78, $\text{M} - 2 \text{ H}$), 262 (98, $\text{M} - 3 \text{ H}$), 234 (58, $\text{M} - \text{CH}_3\text{O}$), 145 (99, $\text{M} - \text{C}_7\text{H}_7\text{N}_2$), 91 (100, $\text{M} - \text{C}_9\text{H}_8\text{N}_3\text{O}$), 28 (98, $\text{M} - \text{C}_{16}\text{H}_{15}\text{NO}$).




Figure 8: FT-IR (KBr) of 1-Benzyl-4-(4-methoxyphenyl)-1H-1,2,3-triazole (4c).




Figure 9: ¹H NMR (300 MHz, CDCl₃) of 1-Benzyl-4-(4-methoxyphenyl)-1H-1,2,3-triazole (4c).




Figure 10: ^{13}C NMR (75MHz, CDCl_3) of 1-Benzyl-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (**4c**).




Figure 11: Mass spectrum of 1-Benzyl-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (**4c**).

1-benzyl-4-(4-(*tert*-butyl)phenyl)-1*H*-1,2,3-triazole (4d) (0.25 g, 88%); white solid (crystals); mp 112–113 °C (from EtOH) (Lit.⁴ 112–114 °C); FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3084, 3035, 2959, 2865, 1495, 1457 (CH₂), 1363, 1221 (N–N=N–), 1189 (C–N), 1071, 1048, 976, 832 (=C–H oop, triazole ring), 739, 719, 693, 559; ¹H NMR: δ H (400 MHz; CDCl₃; Me₄Si) 7.73 (2 H, d, *J* = 8 Hz, Ar-H), 7.63 (1 H, s, C=CH), 7.43–7.21 (7 H, m, Ar-H), 5.58 (2 H, s, CH₂), 1.37 (9 H, s, 3 CH₃); MS, *m/z* 291 (M⁺, 4%), 290 (27, M – H), 289 (88, M – 2 H), 171 (99, M – C₇H₇N₂), 157 (43, M – C₇H₇N₃), 91 (100, M – C₁₂H₁₄N₃), 57 (45, M – C₁₅H₁₂N₃), 29 (96, M – C₁₉H₂₁N).




Figure 12: FT-IR (KBr) of 1-benzyl-4-(4-(*tert*-butyl)phenyl)-1*H*-1,2,3-triazole (**4d**).




Figure 13: ^1H NMR (400 MHz, CDCl_3) of 1-benzyl-4-(4-(*tert*-butyl)phenyl)-1*H*-1,2,3-triazole (**4d**).




Figure 14: Mass spectrum of 1-benzyl-4-(4-(*tert*-butyl)phenyl)-1*H*-1,2,3-triazole (**4d**).

1-benzyl-4-(4-chlorophenyl)-1*H*-1,2,3-triazole (4e) (0.25 g, 95%); white solid (crystals); mp 125–126 °C (from EtOH) (Lit.⁵ 125–127 °C); ¹H NMR: δH (300 MHz; CDCl₃; Me₄Si) 7.74 (2 H, d, *J* = 8.4 Hz, Ar-H), 7.69 (1 H, s, C=CH), 7.40–7.29 (7 H, m, Ar-H), 5.57 (2 H, s, CH₂); ¹³C NMR: δC (75 MHz; CDCl₃; Me₄Si) 147, 134, 133, 129.21, 129.11, 129.01, 128.87, 128.11, 126, 119, 54; MS, *m/z* 269 (M⁺, 8%), 271 (2, M + 2), 268 (60, M – H), 267 (65, M – 2 H), 241 (32, M – N₂), 178 (65, M – C₇H₇), 149 (94, M – C₇H₇N₂), 123 (69, M – C₈H₈N₃), 104 (65, M – C₈H₅ClN₂), 91 (100, M – C₈H₅ClN₃), 28 (62, M – C₁₅H₁₂ClN).




Figure 15: ¹H NMR (300 MHz, CDCl₃) of 1-benzyl-4-(4-chlorophenyl)-1*H*-1,2,3-triazole (**4e**).




Figure 16: ^{13}C NMR (75MHz, CDCl_3) of 1-benzyl-4-(4-chlorophenyl)-1H-1,2,3-triazole (**4e**).




Figure 17: Mass spectrum of 1-benzyl-4-(4-chlorophenyl)-1H-1,2,3-triazole (**4e**).

1-benzyl-4-(4-bromophenyl)-1*H*-1,2,3-triazole (4f) white solid (crystals); mp 144 °C (from EtOH) (Lit.⁵ 143–145 °C); ¹H NMR: δH (300 MHz; CDCl₃; Me₄Si) 7.69 (2 H, d, *J* = 1.8 Hz, Ar-H), 7.67 (1 H, s, C=CH), 7.53 (2 H, d, *J* = 6.9 Hz, Ar-H), 7.29-7.43 (5 H, m, Ar-H), 5.58 (2 H, s, CH₂); ¹³C NMR: δC (75 MHz; CDCl₃; Me₄Si) 147, 134, 131, 129.54, 129.22, 128.89, 128.12, 127, 122, 119, 54; MS, *m/z* 314 (M⁺, 7%), 316 (6, M + 2), 313 (56, M – H), 312 (72, M – 2 H), 285 (13, M – N₂), 194 (88, M – C₈H₈N), 104 (82, M – C₈H₅BrN₂), 91 (100, M – C₈H₅BrN₃), 28 (24, M – C₁₅H₁₂BrN).




Figure 18: ¹H NMR (300 MHz, CDCl₃) of 1-benzyl-4-(4-bromophenyl)-1*H*-1,2,3-triazole (**4f**).




Figure 19: ^{13}C NMR (75MHz, CDCl_3) of 1-benzyl-4-(4-bromophenyl)-1*H*-1,2,3-triazole (**4f**).




Figure 20: Mass spectrum of 1-benzyl-4-(4-bromophenyl)-1*H*-1,2,3-triazole (**4f**).

1-benzyl-4-(4-nitrophenyl)-1*H*-1,2,3-triazole (4g) (0.27 g, 96%); yellow solid (crystals); mp 167–168 °C (from EtOH) (Lit.⁶ 168–170 °C); ¹H NMR: δH (300 MHz; CDCl₃; Me₄Si) 8.27 (2 H, d, *J* = 8.7 Hz, Ar-H), 7.99 (2 H, d, *J* = 8.7 Hz, Ar-H), 7.85 (1 H, s, C=CH), 7.29-7.44 (5 H, m, Ar-H), 5.63 (2 H, s, CH₂); ¹³C NMR: δC (75 MHz; CDCl₃; Me₄Si) 147, 146, 136, 134, 129.33, 129.09, 128, 126, 124, 121, 54; MS, *m/z* 280 (M⁺, 5%), 279 (57, M – H), 278 (68, M – 2 H), 252 (8, M – N₂), 233 (24, M – NO₂), 148 (37, M – C₈H₈N₂), 105 (39, M – C₈H₅N₃O₂), 91 (100, M – C₈H₅N₄O₂), 28 (58, M – C₁₅H₁₂N₂O₂).




Figure 21: ¹H NMR (300 MHz, CDCl₃) of 1-benzyl-4-(4-nitrophenyl)-1*H*-1,2,3-triazole (**4g**).




Figure 22: ^{13}C NMR (75MHz, CDCl_3) of 1-benzyl-4-(4-nitrophenyl)-1H-1,2,3-triazole (**4g**).




Figure 23: Mass spectrum of 1-benzyl-4-(4-nitrophenyl)-1H-1,2,3-triazole (**4g**).

2-(1-benzyl-1*H*-1,2,3-triazol-4-yl)pyridine (4h) (0.21 g, 90%); white solid (crystals); mp 112–113 °C (from EtOH) (Lit.⁷ 113–114 °C); FT-IR (KBr): ν_{max} /cm⁻¹ 3137, 3105, 3084, 3002, 2949, 1599, 1568, 1455 (CH₂), 1419, 1352, 1223 (N–N=N–), 1196 (C–N), 1082, 1044, 996, 857 (=C–H oop, triazole ring), 786, 727, 711, 579; ¹H NMR: δ H (300 MHz; CDCl₃; Me₄Si) 8.55 (1 H, d, *J* = 4.2 Hz, Py-H), 8.19 (1 H, d, *J* = 8.1 Hz, Py-H), 8.06 (1 H, s, C=CH), 7.78 (1 H, td, *J*₁ = 7.8 Hz, *J*₂ = 1.8 Hz, Py-H), 7.41–7.33 (5 H, m, Ar-H, Py-H), 7.24–7.20 (1 H, m, Ar-H), 5.60 (2 H, s, CH₂); ¹³C NMR: δ C (75 MHz; CDCl₃; Me₄Si) 150, 149, 148, 136, 134, 129, 128.86, 128.33, 122, 121, 120, 54. MS, *m/z* 236 (M⁺, 5%), 235 (41, M – H), 234 (82, M – 2 H), 207 (95, M – N₂), 78 (35, M – C₉H₈N₃), 91 (92, M – C₇H₅N₄).




Figure 24: FT-IR (KBr) of 2-(1-benzyl-1*H*-1,2,3-triazol-4-yl)pyridine (**4h**).




Figure 25: ¹H NMR (300 MHz, CDCl₃) of 2-(1-benzyl-1H-1,2,3-triazol-4-yl)pyridine (**4h**).




Figure 26: ¹³C NMR (75 MHz, CDCl₃) of 2-(1-benzyl-1H-1,2,3-triazol-4-yl)pyridine (**4h**).




Figure 27: Mass spectrum of 2-(1-benzyl-1*H*-1,2,3-triazol-4-yl)pyridine (**4h**).

1-(4-chlorobenzyl)-4-phenyl-1*H*-1,2,3-triazole (4i**)** (0.25 g, 93%); white solid (crystals); mp 140–143 °C (from EtOH) (Lit.² 142–145 °C); FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3113, 3083, 3064, 3035, 2933, 1491, 1462 (CH₂), 1411, 1356, 1220 (N–N=N–), 1139 (C–N), 1093, 1080, 1015, 972, 821 (=C–H oop, triazole ring), 805, 764, 688, 497; ¹H NMR: δ H (300 MHz; CDCl₃; Me₄Si) 7.83 (2 H, d, J = 7.6 Hz, Ar-H), 7.69 (1 H, s, C=CH), 7.46–7.32 (5 H, m, Ar-H), 7.27 (2 H, d, J = 8.7 Hz, Ar-H), 5.58 (2 H, s, CH₂); MS, m/z 269 (M⁺, 7%), 271 (2, M + 2), 268 (33, M – H), 266 (75, M – 3 H), 125 (80, M – C₈H₆N₃), 116 (92, M – C₇H₆ClN₂), 102 (66, M – C₇H₆ClN₃), 89 (87), 77 (65, M – C₉H₇ClN₃), 39 (75), 28 (62, M – C₁₅H₁₂ClN).




Figure 28: FT-IR (KBr) of 1-(4-chlorobenzyl)-4-phenyl-1H-1,2,3-triazole (4i).




Figure 29: ^1H NMR (300 MHz, CDCl_3) of 1-(4-chlorobenzyl)-4-phenyl-1H-1,2,3-triazole (4i).




Figure 30: Mass spectrum of 1-(4-chlorobenzyl)-4-phenyl-1*H*-1,2,3-triazole (**4i**).

1-(4-chlorobenzyl)-4-(*p*-tolyl)-1*H*-1,2,3-triazole (4j**)** (0.26 g, 92%); white solid (crystals); mp 141–142 °C (from EtOH) (Lit.² 140–143 °C); FT-IR (KBr): $\nu_{\max}/\text{cm}^{-1}$ 3117, 3090, 3047, 2921, 1492, 1454 (CH_2), 1410, 1356, 1220 ($\text{N}=\text{N}=\text{N}$), 1170 ($\text{C}-\text{N}$), 1081, 1047, 1015, 976, 818 ($=\text{C}-\text{H}$ oop, triazole ring), 767, 517; ^1H NMR: δH (300 MHz; CDCl_3 ; Me_4Si) 7.71 (2 H, d, $J = 8.1$ Hz, Ar-H), 7.65 (1 H, s, $\text{C}=\text{CH}$), 7.39 (2 H, d, $J = 8.4$ Hz, Ar-H), 7.29–7.23 (4 H, m, Ar-H), 5.56 (2 H, s, CH_2), 2.39 (3 H, s, CH_3); MS, m/z 283 (M^+ , 25%), 285 (8, $\text{M} + 2$), 282 (40, $\text{M} - \text{H}$), 281 (85, $\text{M} - 2 \text{H}$), 125 (85, $\text{M} - \text{C}_9\text{H}_8\text{N}_3$), 116 (60, $\text{M} - \text{C}_7\text{H}_6\text{ClN}_3$), 89 (85), 77 (85, $\text{M} - (\text{C}_9\text{H}_7\text{ClN}_3 + \text{CH}_3)$), 28 (82, $\text{M} - \text{C}_{16}\text{H}_{14}\text{ClN}$), 15 (38, $\text{M} - \text{C}_{15}\text{H}_{11}\text{ClN}_3$).




Figure 31: FT-IR (KBr) of 1-(4-chlorobenzyl)-4-(p-tolyl)-1H-1,2,3-triazole (4j).




Figure 32: ^1H NMR (300 MHz, CDCl_3) of 1-(4-chlorobenzyl)-4-(p-tolyl)-1H-1,2,3-triazole (4j).




Figure 33: Mass spectrum of 1-(4-chlorobenzyl)-4-(*p*-tolyl)-1*H*-1,2,3-triazole (**4j**).

1-(4-chlorobenzyl)-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (4k**)** (0.27 g, 90%); white solid (crystals); mp 150–152 °C (from EtOH); elemental analysis: Found: C, 63.99; H, 4.65; N, 13.92. Calc. for C₁₆H₁₄ClN₃O: C, 64.11; H, 4.71; N, 14.02%; FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3121, 3091, 3019, 2958, 2933, 2835, 1616, 1561, 1493, 1453 (CH₂), 1434, 1351, 1302, 1255 (N–N=N–), 1218, 1175 (C–N), 1030, 1016, 976, 818 (=C–H oop, triazole ring), 765; ¹H NMR: δ H (300 MHz; CDCl₃; Me₄Si) 7.76–7.28 (7 H, m, Ar-H, C=CH), 6.96 (2 H, d, *J* = 6.3 Hz, Ar-H), 5.55 (2 H, s, CH₂), 2.86 (3 H, s, CH₃); ¹³C NMR: δ C (75 MHz; CDCl₃; Me₄Si) 159, 148, 134, 133, 129, 127, 123, 118, 114, 55, 53; MS, *m/z* 299 (M⁺, 5%), 301 (2, M + 2), 298 (43, M – H), 297 (95, M – 2 H), 267 (96, M – CH₃O), 146 (42, M – C₇H₆ClN₂), 125 (90, M – C₉H₈N₃O), 89 (95), 76 (91, M – (CH₃O + C₉H₇ClN₃)), 28 (55, M – C₁₆H₁₄ClNO).




Figure 34: Elemental analysis of 1-(4-chlorobenzyl)-4-(4-methoxyphenyl)-1H-1,2,3-triazole (**4k**).




Figure 35: FT-IR (KBr) of 1-(4-chlorobenzyl)-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (**4k**).




Figure 36: ¹³C NMR (300 MHz, CDCl₃) of 1-(4-chlorobenzyl)-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (**4k**).




Figure 37: ^{13}C NMR (75MHz, CDCl_3) of 1-(4-chlorobenzyl)-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (**4k**).




Figure 38: Mass spectrum of 1-(4-chlorobenzyl)-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (**4k**).

4-(4-(*tert*-butyl)phenyl)-1-(4-chlorobenzyl)-1*H*-1,2,3-triazole (4l**)** (0.28 g, 86%); white solid (crystals); mp 153–154 °C (from EtOH); elemental analysis: Found: C, 69.94; H, 5.93; N, 12.63. Calc. for $\text{C}_{19}\text{H}_{20}\text{ClN}_3$: C, 70.04; H, 6.19; N, 12.90%; FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3133, 2959, 2904, 2868, 1492, 1457 (CH_2), 1427, 1361, 1224 (N–N=N–), 1157 (C–N), 1049, 1014, 976, 833 (=C–H oop, triazole ring), 806, 776, 560; ^1H NMR: δH (300 MHz; CDCl_3 ; Me_4Si) 7.75 (2 H, d, $J = 8.4$ Hz, Ar-H), 7.67 (1 H, s, C=CH), 7.45 (2 H, d, $J = 8.4$ Hz, Ar-H), 7.37 (2 H, d, $J = 8.4$ Hz, Ar-H), 7.26 (2 H, t, $J = 8.4$ Hz, Ar-H), 5.55 (2 H, s, CH_2), 1.36 (9 H, s, 3 CH_3); ^{13}C NMR: δC (75 MHz; CDCl_3 ; Me_4Si) 151, 148, 134, 133, 129, 127, 125, 119, 53, 34, 31; MS, m/z 325 (M^+ , 64%), 327 (19, $\text{M} +$

Eager 300 Summarize Results

Date : 01/01/2003 at 03:26:29
Method Name : NCHS
Method Filename : Copy of Copy of N C H S-bkp .mth

Filename	AS Method	Vial

jahanshahi-155		
#	Group Sample Name	Type Weig. Pro.F ---


155 1	R69	UNK 0.872 6.25 ---
Component name	Element %	

Nitrogen%	12.63339214	Calcd. for C ₁₉ H ₂₀ ClN ₃
Carbon%	69.94673157	Nitrogen% 12.90
Hydrogen%	5.936340523	Carbon% 70.04
Sulphur%	0	Hydrogen% 6.19
		Sulphor% 0

1 Sample(s) in Group No : 1

Component Name	Average

Nitrogen%	12.63339214
Carbon%	69.94673157
Hydrogen%	5.936340523
Sulphur%	0



28




Figure 40: FT-IR (KBr) of 4-(4-(*tert*-butyl)phenyl)-1-(4-chlorobenzyl)-1*H*-1,2,3-triazole (4I).




Figure 41: ¹H NMR (300 MHz, CDCl₃) of 4-(4-(*tert*-butyl)phenyl)-1-(4-chlorobenzyl)-1*H*-1,2,3-triazole (4I).




Figure 42: ^{13}C NMR (75MHz, CDCl_3) of 4-(4-(*tert*-butyl)phenyl)-1-(4-chlorobenzyl)-1*H*-1,2,3-triazole (**41**).




Figure 43: Mass spectrum of 4-(4-(*tert*-butyl)phenyl)-1-(4-chlorobenzyl)-1*H*-1,2,3-triazole (**41**).

2-(1-(4-chlorobenzyl)-1*H*-1,2,3-triazol-4-yl)pyridine (4m) (0.24 g, 88%); yellow solid (crystals); mp 113–114 °C (from EtOH) (Lit.² 115–117 °C); FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3113, 3088, 3060, 2925, 2855, 1595, 1568, 1491, 1469 (CH₂), 1419, 1325, 1224 (N–N=N–), 1147 (C–N), 1080, 1046, 1015, 994, 805 (=C–H oop, triazole ring), 784, 768, 739, 677; ¹H NMR: δ H (300 MHz; CDCl₃; Me₄Si) 8.56 (1 H, d, J = 4.2 Hz, Py-H), 8.20 (1 H, d, J = 7.8 Hz, Py-H), 8.07 (1 H, s, C=CH), 7.79 (1 H, td, J_1 = 7.65 Hz, J_2 = 1.8 Hz, Py-H), 7.39–7.22 (5 H, m, Ar-H), 5.58 (2 H, s, CH₂); ¹³C NMR: δ C (75 MHz; CDCl₃; Me₄Si) 150, 149, 148, 136, 134, 132, 129.61, 129.41, 122, 121, 120, 53; MS, m/z 270 (M⁺, 40%), 272 (13, M + 2), 269 (43, M – H), 268 (55, M – 2 H), 242 (43, M – N₂), 125 (100, M – C₇H₅N₄), 117 (96, M – C₇H₆ClN₂), 99 (75, M – (C₈H₇N₄ + Cl)), 103 (50, M – C₇H₆ClN₃), 90 (88), 78 (75, M – C₉H₇ClN₃), 28 (50, M – C₁₄H₁₁ClN₂).




Figure 44: FT-IR (KBr) of 2-(1-(4-chlorobenzyl)-1*H*-1,2,3-triazol-4-yl)pyridine (**4m**).




Figure 45: ¹H NMR (300 MHz, CDCl₃) of 2-(1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)pyridine (4m).




Figure 46: ^{13}C NMR (75MHz, CDCl_3) of 2-(1-(4-chlorobenzyl)-1*H*-1,2,3-triazol-4-yl)pyridine (**4m**).




Figure 47: Mass spectrum of 2-(1-(4-chlorobenzyl)-1*H*-1,2,3-triazol-4-yl)pyridine (**4m**).

1-(4-nitrobenzyl)-4-phenyl-1*H*-1,2,3-triazole (4n**)** (0.25 g, 91%); white solid (crystals); mp 157–158 °C (from EtOH) (Lit.⁸ 156–157 °C); FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3126, 3080, 2962, 2855, 1607, 1517, 1462 (CH_2), 1443, 1348, 1218 ($\text{N}=\text{N}=\text{N}$), 1186 ($\text{C}-\text{N}$), 1071, 1046, 1016, 972, 861, 806 ($=\text{C}-\text{H}$ oop, triazole ring), 764, 726, 693, 513; ^1H NMR: δH (300 MHz; CDCl_3 ; Me_4Si) 8.25 (2 H, d, $J = 8.7$ Hz, Ar-H), 7.84 (2 H, d, $J = 8.7$ Hz, Ar-H), 7.79 (1 H, s, $\text{C}=\text{CH}$), 7.48–7.29 (5 H, m, Ar-H), 5.72 (2 H, s, CH_2); MS, m/z 280 (M^+ , 5%), 279 (21, $\text{M}-\text{H}$), 278 (86, $\text{M}-2\text{H}$), 204 (40, $\text{M}-\text{C}_6\text{H}_5$), 177 (18, $\text{M}-\text{C}_7\text{H}_5\text{N}$), 135 (41, $\text{M}-\text{C}_8\text{H}_6\text{N}_3$), 116 (100, $\text{M}-\text{C}_7\text{H}_6\text{N}_3\text{O}_2$), 78 (85, $\text{M}-\text{C}_9\text{H}_7\text{N}_4\text{O}_2$), 29 (72, $\text{M}-\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_2$).




Figure 48: FT-IR (KBr) of 1-(4-nitrobenzyl)-4-phenyl-1H-1,2,3-triazole (4n).




Figure 49: ^1H NMR (300 MHz, CDCl_3) of 1-(4-nitrobenzyl)-4-phenyl-1H-1,2,3-triazole (4n).




Figure 50: Mass spectrum of 1-(4-nitrobenzyl)-4-phenyl-1*H*-1,2,3-triazole (**4n**).

1-(4-nitrobenzyl)-4-(*p*-tolyl)-1*H*-1,2,3-triazole (4o**)** (0.26 g, 89%); white solid (crystals); mp 145–146 °C (from EtOH) (Lit.⁹ 145–147 °C); FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3094, 3051, 2925, 2855, 1603, 1515, 1455 (CH₂), 1429, 1348, 1287, 1222 (N–N=N–), 1110 (C–N), 1043, 980, 845, 818 (=C–H oop, triazole ring), 801, 730, 514; MS, m/z 294 (M⁺, 5%), 293 (20, M – H), 292 (78, M – 2 H), 249 (43, M – NO₂), 204 (29, M – C₇H₇), 177 (55, M – C₈H₇N), 135 (77, M – C₉H₈N₃), 130 (100, M – C₇H₆N₃O₂), 103 (83, M – C₈H₇N₄O₂), 91 (68, M – C₉H₇N₄O₂), 77 (93, M – (NO₂ + C₁₀H₁₀N₃)), 29 (81, M – C₁₆H₁₄N₂O₂).




Figure 51: FT-IR (KBr) of 1-(4-nitrobenzyl)-4-(*p*-tolyl)-1*H*-1,2,3-triazole (**40**).




Figure 52: Mass spectrum of 1-(4-nitrobenzyl)-4-(*p*-tolyl)-1*H*-1,2,3-triazole (**40**).

4-(4-methoxyphenyl)-1-(4-nitrobenzyl)-1*H*-1,2,3-triazole (4p) (0.26 g, 86%); white solid (crystals); mp 94–96 °C (from EtOH) (Lit.¹⁰ 95–98 °C); FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3125, 3092, 3002, 2941, 2839, 1611, 1556, 1530, 1502, 1452 (CH₂), 1343, 1248 (N–N=N–), 1222, 1174 (C–N), 1107, 1027, 980, 819 (=C–H oop, triazole ring), 845, 727, 608, 538; ¹H NMR: δ H (300 MHz; CDCl₃; Me₄Si) 8.21 (2 H, d, *J* = 8.4 Hz, Ar-H), 7.84 (1 H, s, C=CH), 7.73 (2 H, d, *J* = 8.7 Hz, Ar-H), 7.43 (2 H, d, *J* = 8.4 Hz, Ar-H), 6.94 (2 H, d, *J* = 8.4 Hz, Ar-H), 5.68 (2 H, s, CH₂), 3.83 (3 H, s, OCH₃); MS, *m/z* 310 (M⁺, 5%), 309 (21, M – H), 308 (86, M – 2 H), 279 (95, M – CH₃O), 265 (23, M – NO₂), 146 (97, M – C₇H₆N₃O₂), 119 (44, M – C₈H₇N₄O₂), 77 (34, M – (NO₂ + C₁₀H₁₀N₃O)), 29 (97, M – C₁₆H₁₄N₂O₃).




Figure 53: FT-IR (KBr) of 4-(4-methoxyphenyl)-1-(4-nitrobenzyl)-1*H*-1,2,3-triazole (4p).




Figure 54: ^1H NMR (300 MHz, CDCl_3) of 4-(4-methoxyphenyl)-1-(4-nitrobenzyl)-1*H*-1,2,3-triazole (**4p**).




Figure 55: Mass spectrum of 4-(4-methoxyphenyl)-1-(4-nitrobenzyl)-1*H*-1,2,3-triazole (**4p**).

4-(4-(*tert*-butyl)phenyl)-1-(4-nitrobenzyl)-1*H*-1,2,3-triazole (4q) (0.29 g, 86%); white solid (crystals); mp 145–147 °C (from EtOH); elemental analysis Found: C, 67.67; H, 5.67; N, 16.92. Calc. for C₁₉H₂₀N₄O₂: C, 67.84; H, 5.99; N, 16.66%; FT-IR (KBr): ν_{max} /cm⁻¹ 3117, 3084, 2962, 2900, 2865, 1604, 1516, 1495, 1457 (CH₂), 1346, 1220 (N=N=N-), 1109 (C-N), 1072, 1044, 976, 835 (=C-H oop, triazole ring), 782, 739, 723, 559; ¹H NMR: δ H (300 MHz; CDCl₃; Me₄Si) 8.25 (2 H, d, *J* = 8.7 Hz, Ar-H), 7.77 (3 H, d, *J* = 7.8 Hz, Ar-H, C=CH), 7.48-7.43 (4 H, m, Ar-H), 5.72 (2 H, s, CH₂), 1.36 (9 H, s, 3 CH₃); ¹³C NMR: δ C (75 MHz; CDCl₃; Me₄Si) 151, 148.74, 148.08, 141, 128, 127, 125.64, 125.50, 124, 119, 53, 34, 31; MS, *m/z* 336 (M⁺, 5%), 335 (10, M – H), 334 (28, M – 2 H), 333 (48, M – 3 H), 332 (40, M – 4 H), 290 (20, M – NO₂), 203 (17, M – C₁₀H₁₃), 171 (100, M – C₇H₆N₃O₂), 57 (83, M – C₁₅H₁₁N₄O₂), 28 (37, M – C₁₉H₂₀N₂O₂).




Figure 56: Elemental analysis of 4-(4-(*tert*-butyl)phenyl)-1-(4-nitrobenzyl)-1*H*-1,2,3-triazole (**4q**).




Figure 57: FT-IR (KBr) of 4-(4-(*tert*-butyl)phenyl)-1-(4-nitrobenzyl)-1*H*-1,2,3-triazole (**4q**).




Figure 58: ^1H NMR (300 MHz, CDCl_3) of 4-(4-(*tert*-butyl)phenyl)-1-(4-nitrobenzyl)-1*H*-1,2,3-triazole (**4q**).




figure 59: ^{13}C NMR (75 MHz, CDCl_3) of 4-(4-(*tert*-butyl)phenyl)-1-(4-nitrobenzyl)-1*H*-1,2,3-triazole (**4q**).




Figure 60: Mass spectrum of 4-(4-(*tert*-butyl)phenyl)-1-(4-nitrobenzyl)-1*H*-1,2,3-triazole (**4q**).

2-(1-(4-nitrobenzyl)-1*H*-1,2,3-triazol-4-yl)pyridine (4r**)** (0.23 g, 84%); yellow solid (crystals); mp 175–177 °C (from EtOH) (Lit.¹⁰ 176–179 °C); 3114, 3088, 3056, 3007, 2851, 1603, 1511, 1469 (CH₂), 1418, 1348, 1229 (N=N=N–), 1200, 1147 (C–N), 1078, 1046, 995, 859, 808 (=C–H oop, triazole ring), 786, 729, 510; MS, *m/z* 281 (M⁺, 5%), 280 (27, M – H), 278 (20, M – 3 H), 177 (10, M – C₆H₄N₂), 130 (99, M – C₇H₆N₂O₂), 117 (100, M – C₇H₆N₃O₂), 103 (68, M – C₇H₆N₄O₂), 90 (96, M – (NO₂ + C₇H₅N₄)), 78 (98, M – C₉H₇N₄O₂), 28 (74, M – C₁₄H₁₁N₃O₂).




Figure 61: FT-IR (KBr) of 2-(1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)pyridine (4r).




Figure 62: Mass spectrum of 2-(1-(4-nitrobenzyl)-1*H*-1,2,3-triazol-4-yl)pyridine (**4r**).
1-allyl-4-phenyl-1*H*-1,2,3-triazole (4s**)** (0.16 g, 90%); yellow (crystals); mp 40 °C (from EtOH) (Lit.¹¹ 40–41 °C); FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3131, 3084, 3035, 2953, 2924, 2853, 1642, 1609, 1485, 1464 (CH₂), 1359, 1225 (N–N=N–), 1171 (C–N), 1045, 990, 913, 810 (=C–H oop, triazole ring), 763, 693, 517; MS, m/z 185 (M⁺, 5%), 184 (38, M – H), 183 (27, M – 2 H), 116 (78, M – C₃H₅N₂), 83 (75, M – C₈H₆), 69 (76, M – C₈H₆N), 55 (100, M – C₈H₆N₂), 41 (77, M – C₈H₆N₃), 28 (72, M – C₁₁H₁₁N).




Figure 63: FT-IR (KBr) of 1-allyl-4-phenyl-1*H*-1,2,3-triazole (**4s**).




Figure 64: Mass spectrum of 1-allyl-4-phenyl-1H-1,2,3-triazole (4s).

1-allyl-4-(*p*-tolyl)-1H-1,2,3-triazole¹² (4t) (0.17 g, 87%); white solid (crystals); mp 82-83 °C (from EtOH); FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3125, 3106, 3027, 2978, 2917, 2859, 1642, 1497, 1451 (CH_2), 1339, 1217 ($\text{N}=\text{N}=\text{N}-$), 1171 ($\text{C}-\text{N}$), 1071, 1048, 988, 933, 817 ($=\text{C}-\text{H}$ oop, triazole ring), 768, 726, 519; ^1H NMR: δH (400 MHz; CDCl_3 ; Me_4Si) 7.73-7.67 (2 H, m, Ar-H, $\text{C}=\underline{\text{CH}}$), 7.26-7.16 (3 H, m, Ar-H), 6.06-6.04 (1 H, m, $\text{C}=\underline{\text{CH}}$), 5.40-5.33 (2 H, m, $\underline{\text{H}_2}\text{C}=\text{CH}$), 5.03-4.97 (2 H, m, $\underline{\text{CH}_2}$), 2.35 (3 H, d, $J = 9.6$ Hz, $\underline{\text{CH}_3}$); MS, m/z 199 (M^+ , 36%), 198 (76, $\text{M} - \text{H}$), 197 (75, $\text{M} - 2 \text{H}$), 170 (56, $\text{M} - \text{N}_2$), 143 (36, $\text{M} - \text{C}_3\text{H}_5\text{N}$), 130 (87, $\text{M} - \text{C}_3\text{H}_5\text{N}_2$), 103 (77, $\text{M} - \text{C}_4\text{H}_6\text{N}_3$), 91 (39, $\text{M} - \text{C}_5\text{H}_6\text{N}_3$), 77 (78, $\text{M} - (\text{CH}_3 + \text{C}_5\text{H}_6\text{N}_3)$), 41 (73, $\text{M} - \text{C}_9\text{H}_8\text{N}_3$), 28 (44, $\text{M} - \text{C}_{12}\text{H}_{13}\text{N}$).




Figure 65: FT-IR (KBr) of 1-allyl-4-(*p*-tolyl)-1*H*-1,2,3-triazole (**4t**).





Figure 66: ^1H NMR (400 MHz, CDCl_3) of 1-allyl-4-(*p*-tolyl)-1*H*-1,2,3-triazole (**4t**).



1-

Figure 67: Mass spectrum of 1-allyl-4-(*p*-tolyl)-1*H*-1,2,3-triazole (**4t**).

allyl-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (4u**)** (0.18 g, 84%); white solid (crystals); mp 90–91 °C (from EtOH) (Lit.¹³ 88–89 °C); FT-IR (KBr): $\nu_{\text{max}}/\text{cm}^{-1}$ 3121, 3101, 3051, 2949, 2835, 1618, 1562, 1501, 1455 (CH_2), 1303, 1250 ($\text{N}=\text{N}=\text{N}-$), 1218, 1175 ($\text{C}-\text{N}$), 1078, 1031, 976, 913, 823 ($=\text{C}-\text{H}$ oop, triazole ring), 775, 620, 538; ^1H NMR: δH (300 MHz; CDCl_3 ; Me_4Si) 7.77 (2 H, d, $J = 8.7$ Hz, Ar-H), 7.0 (1 H, s, $\text{C}=\text{CH}$), 6.97 (2 H, d, $J = 8.7$ Hz, Ar-H), 6.14–6.01 (1 H, m, $\text{H}_2\text{C}=\text{CH}$), 5.40–5.33 (2 H, m, $\text{H}_2\text{C}=\text{CH}$), 5.02 (2 H, d, $J = 6$ Hz, CH_2), 3.85 (3 H, s, CH_3); ^{13}C NMR: δC (75 MHz; CDCl_3 ; Me_4Si) 159, 147, 131, 127, 123, 120, 118, 114, 55, 52; MS, m/z 215 (M^+ , 4%), 214 (50, $\text{M} - \text{H}$), 213 (96, $\text{M} - 2\text{H}$), 171 (68, $\text{M} - \text{CH}_2$), 145 (100, $\text{M} - \text{C}_3\text{H}_5$), 131 (41, $\text{M} - \text{C}_3\text{H}_5\text{N}$), 117 (41, $\text{M} - \text{C}_4\text{H}_6\text{N}$), 103 (33, $\text{M} - \text{C}_3\text{H}_5\text{N}_3$), 76 (38, $\text{M} - \text{C}_5\text{H}_6\text{N}_3$), 41 (51, $\text{M} - \text{C}_8\text{H}_6\text{N}_3$), 28 (100, $\text{M} - \text{C}_{11}\text{H}_{11}\text{N}$).




Figure 68: FT-IR (KBr) of 1-allyl-4-(4-methoxyphenyl)-1H-1,2,3-triazole (**4u**).




Figure 69:

69: ^1H NMR (300 MHz, CDCl_3) of 1-allyl-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (**4u**).




Figure 70: ^{13}C NMR (75 MHz, CDCl_3) of 1-allyl-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (**4u**).




Figure 71: Mass spectrum of 1-allyl-4-(4-methoxyphenyl)-1*H*-1,2,3-triazole (**4u**).

1-allyl-4-(4-(*tert*-butyl)phenyl)-1*H*-1,2,3-triazole¹² (4v**)** (0.19 g, 82%); yellow (Oil); FT-IR (KBr): $\nu_{\max}/\text{cm}^{-1}$ 2960, 2903, 2866, 1486, 1459 (CH_2), 1362, 1267 ($\text{N}=\text{N}=\text{N}-$), 1116 ($\text{C}-\text{N}$), 1021, 986, 834 ($=\text{C}-\text{H}$ oop, triazole ring), 616, 561; MS, m/z 241 (M^+ , 4%), 239 (16, $\text{M} - 2 \text{H}$), 172 (32, $\text{M} - \text{C}_3\text{H}_5\text{N}_2$), 142 (46, $\text{M} - (\text{C}_3\text{H}_5 + \text{C}_4\text{H}_9)$), 57 (41, $\text{M} - \text{C}_{11}\text{H}_{10}\text{N}_3$), 41 (44, $\text{M} - \text{C}_{12}\text{H}_{14}\text{N}_3$), 28 (51, $\text{M} - \text{C}_{15}\text{H}_{19}\text{N}$).




Figure 72: FT-IR (KBr) of 1-allyl-4-(4-(*tert*-butyl)phenyl)-1*H*-1,2,3-triazole (4v).




Figure 73: Mass spectrum of 1-allyl-4-(4-(*tert*-butyl)phenyl)-1*H*-1,2,3-triazole (4v).

References

- 1 S. Sun, R. Bai, Y. Gu, *Chem. Eur. J.*, 2014, **20**, 549.
- 2 P. V. Chavan, K. S. Pandit, U. V. Desai, M. A. Kulkarni, P. P. Wadgaonkar, *RSC Adv.*, 2014, **4**, 42137.
- 3 P. N. Liu, H. X. Siyang, L. Zhang, S. K. S. Tse, G. Jia, *J. Org. Chem.*, 2012, **77**, 5844.
- 4 S. Koguchi, K. Nakamura, *Synlett*, 2013, **24**, 2305.
- 5 J. M. Perez, R. Cano, D. J. Ramon, *RSC Adv.*, 2014, **4**, 23943.
- 6 J. Zuxi, X. Peng, F. Enqin, *Synth. Commun.*, 2014, **44**, 68.
- 7 C. Richardson, C. M. Fitchett, F. R. Keene, P. J. Steel, *Dalton Trans.*, 2008, 2534.
- 8 L. Huang, W. Liu, J. Wu, Y. Fu, K. Wang, C. Huo, Z. Du, *Tetrahedron Lett.*, 2014, **55**, 2312.
- 9 Y. Jiang, D. Kong, J. Zhao, W. Zhang, W. Xu, W. Li, G. Xu, *Tetrahedron Lett.*, 2014, **55**, 2410.
- 10 N. Joshi, S. Banerjee, *Tetrahedron Lett.*, 2015, **56**, 4163.
- 11 M. Gupta, M. Gupta, S. Paul, R. Kant, V. K. Gupta, *Monatsh. Chem.*, 2015, **146**, 143.
- 12 E. Tasca, S. G. La, L. Sporni, G. Strukul, A. Scarso, *Green Chem.*, 2015, **17**, 1414.
- 13 S. Kamijo, T. Jin, Z. Huo, Y. Yamamoto, *J. Org. Chem.*, 2004, **69**, 2386.

